Today
+2.14%
5 Days
-3.55%
1 Month
-4.63%
6 Months
-6.63%
Year to Date
-8.30%
1 Year
-25.15%
MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial Advances


| Shareholders | Proportion |
|---|---|
| Agenus, Inc. | 43.70% |
| GKCC, LLC | 9.31% |
| Armen (Garo H.) | 3.47% |
| Vanguard Capital Management, LLC | 1.19% |
| Shareholder Types | Proportion |
|---|---|
| Corporation | 53.02% |
| Individual Investor | 7.38% |
| Investment Advisor | 2.62% |
| Investment Advisor/Hedge Fund | 0.29% |
Related Instruments